scholarly journals Effects of Propranolol on Neurodevelopmental Outcomes in Patients with Infantile Hemangioma: A Case-Control Study

2018 ◽  
Vol 2018 ◽  
pp. 1-6
Author(s):  
Chuan Wang ◽  
Qi Wang ◽  
Bo Xiang ◽  
Siyuan Chen ◽  
Fei Xiong ◽  
...  
Keyword(s):  
Treatment Duration ◽  
Infantile Hemangioma ◽  
Control Group ◽  
Healthy Children ◽  
Neurodevelopmental Outcomes ◽  
Obvious Effect ◽  
Negative Effect ◽  
Initiation Of Therapy ◽  
Propranolol Therapy ◽  
Oral Propranolol

Background. The aim of this study was to examine whether oral propranolol has any effect on neurodevelopment outcomes in young children with problematic infantile hemangiomas (IHs). Methods. Thirty-six children with a diagnosis of problematic IH who were treated with oral propranolol were compared with 34 healthy children with no history of propranolol therapy. Patients received propranolol therapy for at least 3 months. Gesell developmental schedules (GDS) were used to evaluate neurodevelopment outcomes in the two groups. The scores of each GDS domain were compared between the two groups. Results. There were no significant differences in developmental quotient (DQ) values for any of the five domains between the patients and healthy controls (P<0.05). Multiple stepwise regression analyses showed that none of the domains in the control group were influenced by the children’s gender or age (P<0.05). In addition, we found that gender, age at the initiation of therapy, age at the time of the neurodevelopment test, and treatment duration had no effect on any domain of the GDS in the patient group (P>0.05). Conclusion. Propranolol has no obvious effect on neurodevelopmental outcomes in children. Early treatment and treatment duration had no negative effect on central nervous system (CNS) development.

scholarly journals Infantile hemangioma and oral propranolol therapy

2015 ◽  
pp. 148-51
Author(s):  
Mustafa Dilek ◽  
Mervan Bekdaş ◽  
Sevil Bilir Göksügür ◽  
Fatih Demircioğlu ◽  
Zehra Karataş ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Therapy ◽  
Oral Propranolol

Recurrence rate of infantile hemangioma after oral propranolol therapy

2020 ◽  
Author(s):  
Giovanni Frongia ◽  
Ji-Oun Byeon ◽  
Arianeb Mehrabi ◽  
Patrick Günther
Keyword(s):  
Recurrence Rate ◽  
Infantile Hemangioma ◽  
Propranolol Therapy ◽  
Oral Propranolol

Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants

2018 ◽  
Vol 14 (3) ◽  
pp. 254-258 ◽  
Author(s):  
Giovanni Frongia ◽  
Ji-Oun Byeon ◽  
Raoul Arnold ◽  
Arianeb Mehrabi ◽  
Patrick Günther
Keyword(s):  
Infantile Hemangioma ◽  
Retrospective Evaluation ◽  
Propranolol Therapy ◽  
Oral Propranolol

scholarly journals Propranolol therapy in infantile hemangioma: correlation of age and duration of treatment to the outcomes

2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Ali Farooq Al-Mayoof ◽  
Ali Egab Joda ◽  
Osama Esmaeel Almushhadany
Keyword(s):  
Prospective Study ◽  
Surface Area ◽  
Inverse Correlation ◽  
Infantile Hemangioma ◽  
Vascular Tumor ◽  
Duration Of Treatment ◽  
The Difference ◽  
Initiation Of Therapy ◽  
A Prospective Study ◽  
Propranolol Therapy

Abstract Background Infantile hemangioma (IH) is the commonest vascular tumor affecting children that appears in the first 2 weeks of life and follows a proliferative phase that continues during the first year of life. After then, it undergoes involution, which lasts for several months or years depending on the size, site, gender, and development of complications. The purpose of this prospective study was to evaluate the correlation of age and duration of propranolol therapy to the outcomes of infantile hemangioma. Methods A prospective study included 28 patients with IH in which the propranolol therapy was initiated in a dose of 3 mg/kg/day divided into two to three doses. The surface area of IH was calculated monthly using AutoCAD software. Treatment with propranolol was discontinued when there was no more decrease in the surface area for two consecutive visits. Eleven males and 17 females completed the study. The age at initiation of therapy ranged from 2 to 16 months while at the end of therapy it was 9 to 23 months. Results The mean difference percent of surface area at 6 months was (51.1 ± 16.3), while at the end of the treatment course was (75.0±16.8) which was statistically significant (P < 0.0001). In addition, a significant inverse correlation was found between the age at the beginning of treatment and the difference percent of surface area. A similar inverse correlation was observed between the age at the beginning of treatment and the duration of treatment. Conclusion In addition to the safety and efficacy of propranolol therapy for IH, a higher response rate can be gained with early treatment and a prolonged course of therapy. In addition, propranolol therapy should be continued until there is no more response for two consecutive months regardless of the age of therapy initiation and the duration of treatment.

scholarly journals Oral propranolol therapy in 23 infants with infantile hemangioma

2018 ◽  
Vol 45 (6) ◽  
pp. 517-524 ◽  
Author(s):  
Jaeyoon Kim ◽  
Jong Won Hong ◽  
Tai Suk Roh ◽  
Won Jai Lee
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Therapy ◽  
Oral Propranolol

NATRIURETIC PEPTIDES LEVEL AND THE STATUS OF THE RENIN – ANGIOTENSIN-ALDOSTERONE SYSTEM IN CHRONIC KIDNEY DISEASE IN PATIENTS WITH CONGENITAL MALFORMATIONS OF THE URINARY SYSTEM

2018 ◽  
Vol 22 (5) ◽  
pp. 45-50
Author(s):  
A. M. Mambetova ◽  
A. M. Inarokova ◽  
N. N. Shabalova ◽  
D. V. Bizheva ◽  
A. T. Mahiyeva
Keyword(s):  
Congenital Malformations ◽  
Control Group ◽  
Healthy Children ◽  
Urinary System ◽  
Renin Angiotensin Aldosterone System ◽  
Natriuretic Hormone ◽  
Renin Angiotensin ◽  
Group I ◽  
The Status ◽  
Sick Children

THE AIM. To determine the concentration of natriuretic peptide in the blood serum in children with congenital malformations of the urinary system (CM US) and to compare with the activity of renin-angiotensin-aldosterone system (RAAS).MATERIALS AND METHODS.119 patients with CM US aged 3 to 18 years were examined. A control group of 10 clinically healthy children. 3 groups were assigned: group I – 55 children with  congenital vesicoureteral reflux, and group II – 34 children with  congenital hydronephrosis and ureterohydronephrosis, III group – 30 children with other forms of dysembryogenesis of the US. Following indicators were identified by ELISA in the blood: renin, aldosterone,  N – terminal propeptide natriuretic hormone (NT-рroВNР). RESULTS.NT-рroВNР, renin and aldosterone hyperproduction were diagnosed in 59,6%, 69,7%, 54.6 % of sick children relatively. Concentrations were higher in all variants of  malformations in comparison with the control group. Significant  differences were revealed in obstructive species, where arterial  hypertension (AH) was diagnosed more often. Patients with AH  recorded significantly higher concentrations of NT-proВNР and renin.CONCLUSION.The key point in pathological processes developmentand progression in the cardiovascular system and kidneys is the  activation of RAAS. The system of natriuretic factors is important in maintaining the compensated state of patients due to the blockade of RAAS.

Sign in / Sign up

Export Citation Format

Share Document